Linking Prescriptions of Hemophilia Treatments 'Greenzin-F' and 'Greenmono'
[Asia Economy Reporter Chunhee Lee] GC Green Cross announced on the 30th that it has launched 'WAPPS-HEMO,' a management software tailored to individual hemophilia patients. This is the first time a domestic pharmaceutical company has released such a product.
WAPPS-HEMO was developed to assist medical professionals prescribing GC Green Cross's hemophilia treatments ‘Greenzin-F’ and ‘Greenmono’ in predicting patients' pharmacokinetic profiles to determine appropriate dosage and intervals. Patients can also proactively manage their condition by checking their predicted blood coagulation factor levels through a dedicated mobile application.
GC Green Cross developed WAPPS-HEMO in collaboration with Canada's McMaster University and the University of Waterloo. The platform owned by these universities was integrated with GC Green Cross's population pharmacokinetic (Population PK) models for Greenzin-F and Greenmono to complete the software.
Recently, the method for determining dosage and administration of blood coagulation factors in hemophilia patients is shifting from weight (kg)-based to patient-specific pharmacokinetic (PK)-based approaches. Since each hemophilia patient has very different pharmacokinetic profiles, such as the half-life of blood coagulation factors, there were many limitations in predicting individual dosages based solely on weight.
Choi Bong-gyu, head of the Data Science Team at GC Green Cross, stated, “Through personalized treatment for domestic hemophilia patients, we expect to improve medication adherence, reduce bleeding rates, lower overall medical costs, and simultaneously enhance patients' quality of life. We will continue to make every effort to create an environment where patients suffering from rare diseases can receive optimal treatment tailored to themselves.”
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
